Effect of erythropoietin on bone marrow mononuclear cells

Stem/progenitor cells are considered an alternative method of heart failure therapy by promoting regeneration of damaged myocardium in myocardial infarction. Effectiveness of cell therapy depends on the population composition and functional activity of the cell graft, and, in turn, it depends on the...

Full description

Bibliographic Details
Main Authors: A. P. Lykov, M. A. Surovtseva, O. V. Poveshchenko, A. M. Chernyavsky, A. V. Fomichev, N. A. Bondarenko, I. I. Kim
Format: Article
Language:Russian
Published: St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists 2020-01-01
Series:Медицинская иммунология
Subjects:
Online Access:https://www.mimmun.ru/mimmun/article/view/1807
_version_ 1797197899600232448
author A. P. Lykov
M. A. Surovtseva
O. V. Poveshchenko
A. M. Chernyavsky
A. V. Fomichev
N. A. Bondarenko
I. I. Kim
author_facet A. P. Lykov
M. A. Surovtseva
O. V. Poveshchenko
A. M. Chernyavsky
A. V. Fomichev
N. A. Bondarenko
I. I. Kim
author_sort A. P. Lykov
collection DOAJ
description Stem/progenitor cells are considered an alternative method of heart failure therapy by promoting regeneration of damaged myocardium in myocardial infarction. Effectiveness of cell therapy depends on the population composition and functional activity of the cell graft, and, in turn, it depends on the conditions of microenvironment. Cultivation of stem/progenitor cells with erythropoietin stimulates proliferative potential causing in vitro resistance to hypoxia, and in vivo stimulation of angiogenesis. We aimed for assessing effects of erythropoietin upon hematopoietic cells. We studied some effects of short-term incubation of bone marrow mononuclear cells (BM-MNCs) in patients with coronary heart disease (CHD) with erythropoietin upon cellular phenotype, cell cycle, apoptosis and their proliferative potential. BM-MNCs were isolated from bone marrow aspirate from patients with CHD in a density gradient, then incubated for 60 minutes with erythropoietin (33.4 IU/ml). Using flow cytometric assay of the total BM-MNCs pool, we have shown there endothelial progenitor cells at different stages of maturation and differentiation, mesenchymal stem cells are. Their total number did not exceed 30%. Short-term incubation of BM-MNCs with erythropoietin reduces expression of CD184 “homing receptor” molecules on CD34+ cells, and causes increase of CD184 on CD31+ cells in the BM-MNCs pool (p < 0.05). In addition, erythropoietin has been shown to cause a delay of CD34+ cells in the resting phase (G0G1), reduce a proportion of cells in the synthetic phase (S) and mitosis (G2/M) (p<0.05), and does not affect apoptosis, as shown by Annexin V-FITC Apoptosis Detection Kit. Erythropoietin had no significant effects on expression on BM-MNCs surface molecules involved in providing adhesion, such as CD18, CD29, CD44, CD49a, CD54, CD62E, CD146, and CD202b. MTT-method has shown that the short-term preincubation of BM-MNCs with erythropoietin contributed to a significant decrease in proliferative activity of BM-MNCs (p < 0.05). However, there was a tendency towards increased resistance of erythropoietin-pretreated BM-MNCs to oxidative stress induced by hydrogen peroxide. We have also revealed a correlation between the numbers of endothelial progenitor cells at different stages of differentiation, and numbers of hematopoietic stem cells in the total BM-MNCs pool. The number of CD34+/CD133+, CD34- / CD31+, CD45+/EpoR+, and CD34+/EpoR+ in BM-MNCs pool are dependent on the age of patients. Hence, a short-term incubation of BM-MNCs with erythropoietin promotes the cells to be retained in resting phase of the cell cycle, thus, in turn, helping to reduce proliferative potential of BM-MNCs.
first_indexed 2024-03-08T05:48:54Z
format Article
id doaj.art-9aac16fc13a64c96b43b3b747b267a74
institution Directory Open Access Journal
issn 1563-0625
2313-741X
language Russian
last_indexed 2024-04-24T06:51:18Z
publishDate 2020-01-01
publisher St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
record_format Article
series Медицинская иммунология
spelling doaj.art-9aac16fc13a64c96b43b3b747b267a742024-04-22T13:07:44ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2020-01-0122113514210.15789/1563-0625-EEO-18071220Effect of erythropoietin on bone marrow mononuclear cellsA. P. Lykov0M. A. Surovtseva1O. V. Poveshchenko2A. M. Chernyavsky3A. V. Fomichev4N. A. Bondarenko5I. I. Kim6Research Institute of Clinical and Experimental Lymphology, Branch of the Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences; E. Meshalkin National Medical Research CenterResearch Institute of Clinical and Experimental Lymphology, Branch of the Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences; E. Meshalkin National Medical Research CenterResearch Institute of Clinical and Experimental Lymphology, Branch of the Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences; E. Meshalkin National Medical Research CenterE. Meshalkin National Medical Research CenterE. Meshalkin National Medical Research CenterResearch Institute of Clinical and Experimental Lymphology, Branch of the Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences; E. Meshalkin National Medical Research CenterResearch Institute of Clinical and Experimental Lymphology, Branch of the Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences; E. Meshalkin National Medical Research CenterStem/progenitor cells are considered an alternative method of heart failure therapy by promoting regeneration of damaged myocardium in myocardial infarction. Effectiveness of cell therapy depends on the population composition and functional activity of the cell graft, and, in turn, it depends on the conditions of microenvironment. Cultivation of stem/progenitor cells with erythropoietin stimulates proliferative potential causing in vitro resistance to hypoxia, and in vivo stimulation of angiogenesis. We aimed for assessing effects of erythropoietin upon hematopoietic cells. We studied some effects of short-term incubation of bone marrow mononuclear cells (BM-MNCs) in patients with coronary heart disease (CHD) with erythropoietin upon cellular phenotype, cell cycle, apoptosis and their proliferative potential. BM-MNCs were isolated from bone marrow aspirate from patients with CHD in a density gradient, then incubated for 60 minutes with erythropoietin (33.4 IU/ml). Using flow cytometric assay of the total BM-MNCs pool, we have shown there endothelial progenitor cells at different stages of maturation and differentiation, mesenchymal stem cells are. Their total number did not exceed 30%. Short-term incubation of BM-MNCs with erythropoietin reduces expression of CD184 “homing receptor” molecules on CD34+ cells, and causes increase of CD184 on CD31+ cells in the BM-MNCs pool (p < 0.05). In addition, erythropoietin has been shown to cause a delay of CD34+ cells in the resting phase (G0G1), reduce a proportion of cells in the synthetic phase (S) and mitosis (G2/M) (p<0.05), and does not affect apoptosis, as shown by Annexin V-FITC Apoptosis Detection Kit. Erythropoietin had no significant effects on expression on BM-MNCs surface molecules involved in providing adhesion, such as CD18, CD29, CD44, CD49a, CD54, CD62E, CD146, and CD202b. MTT-method has shown that the short-term preincubation of BM-MNCs with erythropoietin contributed to a significant decrease in proliferative activity of BM-MNCs (p < 0.05). However, there was a tendency towards increased resistance of erythropoietin-pretreated BM-MNCs to oxidative stress induced by hydrogen peroxide. We have also revealed a correlation between the numbers of endothelial progenitor cells at different stages of differentiation, and numbers of hematopoietic stem cells in the total BM-MNCs pool. The number of CD34+/CD133+, CD34- / CD31+, CD45+/EpoR+, and CD34+/EpoR+ in BM-MNCs pool are dependent on the age of patients. Hence, a short-term incubation of BM-MNCs with erythropoietin promotes the cells to be retained in resting phase of the cell cycle, thus, in turn, helping to reduce proliferative potential of BM-MNCs.https://www.mimmun.ru/mimmun/article/view/1807erythropoietinbone marrowmononuclear cellsphenotypecell cycleapoptosisproliferation
spellingShingle A. P. Lykov
M. A. Surovtseva
O. V. Poveshchenko
A. M. Chernyavsky
A. V. Fomichev
N. A. Bondarenko
I. I. Kim
Effect of erythropoietin on bone marrow mononuclear cells
Медицинская иммунология
erythropoietin
bone marrow
mononuclear cells
phenotype
cell cycle
apoptosis
proliferation
title Effect of erythropoietin on bone marrow mononuclear cells
title_full Effect of erythropoietin on bone marrow mononuclear cells
title_fullStr Effect of erythropoietin on bone marrow mononuclear cells
title_full_unstemmed Effect of erythropoietin on bone marrow mononuclear cells
title_short Effect of erythropoietin on bone marrow mononuclear cells
title_sort effect of erythropoietin on bone marrow mononuclear cells
topic erythropoietin
bone marrow
mononuclear cells
phenotype
cell cycle
apoptosis
proliferation
url https://www.mimmun.ru/mimmun/article/view/1807
work_keys_str_mv AT aplykov effectoferythropoietinonbonemarrowmononuclearcells
AT masurovtseva effectoferythropoietinonbonemarrowmononuclearcells
AT ovpoveshchenko effectoferythropoietinonbonemarrowmononuclearcells
AT amchernyavsky effectoferythropoietinonbonemarrowmononuclearcells
AT avfomichev effectoferythropoietinonbonemarrowmononuclearcells
AT nabondarenko effectoferythropoietinonbonemarrowmononuclearcells
AT iikim effectoferythropoietinonbonemarrowmononuclearcells